Bregni G, Vandeputte C, Pretta A, Senti C, Trevisi E, Acedo Reina E, et al. Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancer. AO [Internet]. 2021 Apr. 3 [cited 2026 Jun. 1];60(4):549-53. Available from: https://medicaljournalssweden.se/actaoncologica/article/view/21484